Catalyst Pharmaceuticals (CPRX) Gross Profit (2019 - 2026)

Catalyst Pharmaceuticals' Gross Profit history runs 8 years deep, the most recent figure standing at $134.9 million for Q1 2026.

• Quarterly Gross Profit rose 9.23% year-over-year to $134.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $513.1 million (up 11.45% YoY) and the FY2025 annual result came in at $501.7 million, up 18.64% from the prior year.
• Gross Profit was $134.9 million for Q1 2026 at Catalyst Pharmaceuticals, up from $126.5 million in the prior quarter.
• Across five years, Gross Profit topped out at $134.9 million in Q1 2026 and bottomed at $37.2 million in Q1 2022.
• A 5-year average of $93.3 million and a median of $94.8 million in 2023 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2023 — Gross Profit surged 102.75% — and 2025, when it gained 5.29%.
• Catalyst Pharmaceuticals' Gross Profit stood at $49.6 million in 2022, then soared by 91.19% to $94.8 million in 2023, then climbed by 26.82% to $120.2 million in 2024, then rose by 5.29% to $126.5 million in 2025, then gained by 6.62% to $134.9 million in 2026.
• Business Quant data shows CPRX's Gross Profit at $134.9 million in Q1 2026, $126.5 million in Q4 2025, and $125.7 million in Q3 2025.